{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:23:39Z","timestamp":1791563019640,"version":"4.3.4"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Based on the FDA Adverse Event Reporting System (FAERS) database, this study aims to explore signals of ocular-related adverse events associated with cyclin-dependent kinase 4\/6 inhibitors (CDK4\/6 inhibitors), providing a reference for clinical medication safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data on ocular adverse events (OAEs) related to CDK4\/6 inhibitors from the 1st quarter of 2015 to the 3rd quarter of 2024 were downloaded from the official website of the FAERS database. The ROR, PRR, and BCPNN methods were employed to evaluate the correlation between CDK4\/6 inhibitors and OAEs. A disproportionality analysis was conducted to assess the risk of ocular toxicity. Multivariate logistic regression analysis was used to explore influencing factors. Data processing, analysis and visualization were performed using R software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1974 OAEs reports were associated with CDK4\/6 inhibitors, including 86 for Abemaciclib, 1,449 for Palbociclib, and 439 for Ribociclib. This study identified 66 OAEs signals related to CDK4\/6 inhibitors. Myopia accounted for the highest proportion of serious cases (57.14%), while Glaucoma had the highest proportion of death cases (13.64%). There were 41 positive signals, among which Dark circles under eyes, Eye disorder, Cataract, and Blindness posed significant risks. Multivariate logistic regression analysis revealed that Ribociclib showed higher ocular toxicity than Abemaciclib (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The current study supports concerns about the risk of OAEs when breast cancer patients use CDK4\/6 inhibitors. Clinicians should raise awareness, conduct multidisciplinary assessments\/management, and remind patients to pay attention to clinical symptoms. The potential differences among CDK4\/6 inhibitors deserve further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1668446","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T06:22:47Z","timestamp":1762410167000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Ocular toxicity events of cyclin-dependent kinase 4\/6 inhibitors in breast cancer: a pharmacovigilance study based on the faers database"],"prefix":"10.3389","volume":"16","author":[{"given":"Mengdi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongqing","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minmin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangxi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"B1","volume-title":"EMA european public assessment report","year":"2022"},{"key":"B2","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.survophthal.2023.10.002","article-title":"Ocular surface toxicities associated with modern anticancer therapies","volume":"69","author":"Boucher","year":"2024","journal-title":"Surv. Ophthalmol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","article-title":"Inhibiting CDK4\/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences","volume":"81","author":"Braal","year":"2021","journal-title":"Drugs"},{"key":"B4","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1634\/theoncologist.2017-0423","article-title":"Estrogen receptor-positive breast cancer: exploiting signaling pathways implicated in endocrine resistance","volume":"23","author":"Brufsky","year":"2018","journal-title":"Oncologist"},{"key":"B5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.clbc.2022.02.002","article-title":"Ocular toxicity in breast cancer management: manual for the oncologist","volume":"22","author":"Canino","year":"2022","journal-title":"Clin. Breast Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1200\/JCO.2012.45.6574","article-title":"Prevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy","volume":"31","author":"Chan","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1002\/ijc.34848","article-title":"Ocular toxicity associated with anti-HER2 agents in breast cancer: a pharmacovigilance analysis using the FAERS database","volume":"154","author":"Chen","year":"2024","journal-title":"Int. J. Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1349636","DOI":"10.3389\/fimmu.2024.1349636","article-title":"Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data","volume":"15","author":"Ding","year":"2024","journal-title":"Front. Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/pds.3561","article-title":"AERS spider: an online interactive tool to mine statistical associations in adverse event reporting system","volume":"23","author":"Grigoriev","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3892\/ijmm.2022.5184","article-title":"CDK4\/6 inhibitor resistance mechanisms and treatment strategies (review)","volume":"50","author":"Huang","year":"2022","journal-title":"Int. J. Mol. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ejca.2013.10.016","article-title":"Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review","volume":"50","author":"Huillard","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3390\/healthcare10030420","article-title":"A standardized dataset of a spontaneous adverse event reporting system","volume":"10","author":"Khaleel","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.annonc.2020.11.005","article-title":"Prevention and management of dermatological toxicities related to anticancer agents: ESMO clinical practice guidelines\u2606","volume":"32","author":"Lacouture","year":"2021","journal-title":"Ann. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.1038\/s41388-019-0695-8","article-title":"Lysosomal trapping of palbociclib and its functional implications","volume":"38","author":"Llanos","year":"2019","journal-title":"Oncogene"},{"key":"B16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2174\/1874364101711010298","article-title":"Presumed chemotherapy-induced optic neuropathy and maculopathy: a case report","volume":"11","author":"Mathew","year":"2017","journal-title":"Open Ophthalmol. J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-Positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s11096-020-01018-z","article-title":"Aromatase inhibitors associated osteonecrosis of jaw: signal refining to identify pseudo safety signals","volume":"42","author":"Neha","year":"2020","journal-title":"Int. J. Clin. Pharm."},{"key":"B19","volume-title":"EMA european public assessment report","year":"2022"},{"key":"B20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40264-019-00873-8","article-title":"Comparing acute kidney injury reports among antibiotics: a pharmacovigilance study of the FDA adverse event reporting system (FAERS)","volume":"43","author":"Patek","year":"2020","journal-title":"Drug Saf."},{"key":"B21","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1080\/14740338.2023.2251380","article-title":"Ocular toxicities associated with antibody drug conjugates and immunotherapy in oncology: clinical presentation, pathogenesis, and management strategies","volume":"22","author":"Raheem","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"B22","volume-title":"EMA european public assessment report","year":"2022"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1016\/j.jcjo.2019.11.003","article-title":"Ribociclib-associated vortex keratopathy","volume":"55","author":"Saeed","year":"2020","journal-title":"Can. J. Ophthalmol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1056\/NEJMra1012354","article-title":"Genomics and the eye","volume":"364","author":"Sheffield","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future","volume":"395","author":"Spring","year":"2020","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B27","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1177\/10781552221101799","article-title":"Vortex keratopathy associated with ribociclib","volume":"29","author":"T\u00fcrkel","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1127128","DOI":"10.3389\/fimmu.2023.1127128","article-title":"Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1093\/annonc\/mdz278","article-title":"Myelopreservation with the CDK4\/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib\/randomized phase II trial","volume":"30","author":"Weiss","year":"2019","journal-title":"Ann. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1600-0420.2006.00737.x","article-title":"Ocular presentations of breast cancer","volume":"85","author":"Wickremasinghe","year":"2007","journal-title":"Acta Ophthalmol. Scand."},{"key":"B32","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/s1350-9462(99)00018-x","article-title":"Expression of cyclin-dependent kinase inhibitors during corneal wound repair","volume":"19","author":"Zieske","year":"2000","journal-title":"Prog. Retin Eye Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1668446\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:36:36Z","timestamp":1762428996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1668446\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":31,"alternative-id":["10.3389\/fphar.2025.1668446"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1668446","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"article-number":"1668446"}}